Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NDRA vs MYGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MYGN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)
MYGN Overall Winner
6-Pillar Tally: NDRA 2 – 4 MYGN
Matrix Metrics: NDRA 4 – 6 MYGN
As of Nov 16, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas MYGN carries 46.3/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin).
- Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NDRA vs MYGN
NDRA
ENDRA Life Sciences Inc. Common Stock
$4.42
+0.23% 1D
Market Cap
$6.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.71β · 48% Vol
Unified Composite Score
44.7
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
MYGN
Head-to-Head Winner
Myriad Genetics Inc
$5.57
-1.59% 1D
Market Cap
$542.9M
TTM Revenue
$804M
Forward P/E
54.0x
Beta / 30D Vol
0.68β · 122% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 44.0
Flow 56.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (NDRA 2 – 4 MYGN)
1. Valuation Multiples
MYGN
Forward P/E
N/M
54.0x
Trailing P/E
N/M
54.0x
PEG Ratio
N/M
1.40x
EV / Revenue
N/M
0.8x
2. Growth & Scale
MYGN
Revenue Growth (YoY)
+0.0%
-1.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$804M
Market Cap
$6.6M
$542.9M
3. Profitability & Quality
NDRA
Gross Margin
N/A
68.3%
Operating Margin
0.0%
-13.3%
Net Profit Margin
0.0%
-16.1%
Return on Equity (ROE)
-152.0%
-40.2%
4. Balance Sheet & Cash Flow
NDRA
Cash Generation (TTM)
-$8.0M
-$38M
Cash Flow Margin
N/A
-4.7%
Net Cash / Leverage
$104,744 Net Debt (0.26x D/E)
$102M Net Debt (0.78x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MYGN
Options Structure Phase
UNCLASSIFIED
SURGE
Current IV / %ile
N/A (N/A)
124.6% (22nd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat
MYGN
OpEx & R&D Intensity
N/A
81.6% of Rev ($656M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NDRA (4) vs MYGN (6)| Institutional Metric | NDRA | MYGN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.6M | $542.9M | MYGN | |
| Trailing P/E Ratio | N/M | 54.0x | MYGN | |
| Forward P/E Ratio | N/M | 54.0x | MYGN | |
| Revenue Growth (YoY) | +0.0% | -1.5% | NDRA | |
| Operating Margin (TTM) | 0.0% | -13.3% | NDRA | |
| Net Profit Margin | 0.0% | -16.1% | NDRA | |
| Return on Equity (ROE) | -152.0% | -40.2% | MYGN | |
| 52-Week Range Position | 37% ($3–$7) | 53% ($3–$8) | MYGN | |
| Beta / 30D Volatility | 0.71β · 48% Vol | 0.68β · 122% Vol | NDRA | |
| Unified Institutional Score | 44.7 / 100 (HOLD) | 46.3 / 100 (HOLD) | MYGN | |
| Trailing 12M Revenue (USD) | N/A | $804M | Scale | |
| Gross Profit Margin (TTM) | N/A | 68.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 1.40x PEG · 0.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$8.0M ($104,744 Net Debt (0.26x D/E)) | -$38M ($102M Net Debt (0.78x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MYGN +46.7 pp
3M Horizon
MYGN +96.08 pp
6M Horizon
MYGN +70.9 pp
1Y Horizon
MYGN +20.44 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NDRA Revenue | MYGN Revenue | NDRA Op. Margin | MYGN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $740M | -146080.5% | 16.4% | MYGN |
| FY2019 | N/A | $850M | N/A | 0.9% | MYGN |
| FY2020 | N/A | $560M | N/A | -52.0% | MYGN |
| FY2021 | N/A | $690M | N/A | -27.6% | MYGN |
| FY2022 | N/A | $680M | N/A | -20.7% | MYGN |
| FY2023 | N/A | $750M | N/A | -34.2% | MYGN |
| FY2024 | N/A | $840M | N/A | -14.7% | MYGN |
| FY2025 | N/A | $820M | N/A | -47.0% | MYGN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NDRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MYGN
SURGE
Current IV
124.6%
IV Percentile
22nd %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NDRA Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MYGN Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
81.6% of Rev ($656M)
90D Engineering Disclosures
0 Published
Investor FAQ NDRA vs MYGN Key Questions & Quantitative Answers
As of Nov 16, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas MYGN carries 46.3/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MYGN leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MYGN at -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NDRA cumulative revenue shifted N/A while MYGN shifted +10.8%. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus 81.6% of Rev ($656M) (0 disclosures) for MYGN.
MYGN screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus MYGN (-40.2% ROE) capital efficiency.
In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.68β · 122% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MYGN vs NDRA · Reverse Pair
MYGN vs INCY
· Sector Peer
MYGN vs ALKS
· Sector Peer
MYGN vs NBIX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking